Radiation and Immunotherapy for Advanced Lung Cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer, confirmed by a biopsy.
- You have more than 3 areas where the cancer has spread to other parts of the body.
- No brain metastases, or any brain metastases must be stable and not growing.
- Your cancer does not have certain genetic changes (EGFR, ALK, ROS, BRAF, MET, RET).
- You are between 18 and 75 years old and in fairly good health (able to do daily activities).
- You are willing and able to have a special scan (PET-CT) and to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
This trial compares two treatment plans for stage III lung cancer that can't be removed by surgery. It tests whether starting with a combination of immunotherapy, targeted therapy, and chemotherapy before usual chemoradiation works better than the usual approach, and whether continuing immunotherapy after treatment helps people live longer.
Hear when a new NSCLC Stage IV Without EGFR/ALK Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.